title: Dual versus triple therapy in eradication of Helicobacter pylori.
abstract: OBJECTIVE
  Duodenal ulcers should be treated by eradication of Helicobacter pylori. This study compared the efficacy of a proton pump inhibitor together with one or two antibiotics in eradication therapy.
  
  
  METHODS
  177 patients who were H. pylori positive were randomized to receive 14 days of either: lansoprazole 30 mg bd and amoxicillin 1 g bd (LA), omeprazole 20 mg bd and amoxicillin 1 g bd (OA) or lansoprazole 30 mg bd, amoxicillin 1 g bd and clarithromycin 500 mg bd (LAC). The efficacy was assessed at four weeks and at six months after the end of treatment. Biopsies were taken for culture and bacterial sensitivity testing at inclusion and at four weeks after the end of treatment.
  
  
  RESULTS
  149 patients were evaluated for efficacy. The eradication rate was significantly higher in LAC (96%) compared to LA (51%) and OA (64%) treatments (P < 0.001). At baseline 17%, 21% and 19% of the patients in the LA, OA and LAC groups, respectively, were resistant to metronidazole and only one patient was resistant to clarithromycin. Post-treatment, four patients had acquired metronidazole resistance.
  
  
  CONCLUSIONS
  LAC is more effective than LA and OA for eradication of H. pylori in duodenal ulcer disease.
authors.affiliation: Department of Surgery, Blekinge County Hospital, 371 85 Karlskrona, Sweden. bo.ohlin@itblekinge.se
authors.forename: B
authors.initials: B
authors.lastname: Ohlin
authors.forename: A
authors.initials: A
authors.lastname: Cederberg
authors.forename: T
authors.initials: T
authors.lastname: Kjellin
authors.forename: E
authors.initials: E
authors.lastname: Kullman
authors.forename: K
authors.initials: K
authors.lastname: Melén
authors.forename: C Staël
authors.initials: CS
authors.lastname: von Holstein
authors.forename: M
authors.initials: M
authors.lastname: Thoring
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D014945:Wound Healing
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole